


**In the claims:**

**Claims 1 to 33 (cancelled).**

**Claim 34 (previously presented)** A N-acyl dipeptidic compound of the formula



(I)


wherein R<sub>1</sub> and R<sub>2</sub> are each an acyl moiety of a saturated or unsaturated carboxylic acid of 2 to 24 carbon atoms unsubstituted or substituted with at least one member selected from the group consisting of hydroxyl, alkyl and alkoxy of 1 to 24 carbon atoms, amino, acyloxy of an organic carboxylic acid of 1 to 24 carbon atoms and acylamino and acylthio of a carboxylic acid of 1 to 24 carbon atoms and alkylthio of 1 to 24 carbon atoms, m, p and q are integers from 1 to 10, n is an integer from 0 to 10, X and Y are independently hydrogen or an acid group selected from the group consisting of

- carboxy [(C<sub>1-5</sub>)alkyl]
- CH-[(CH<sub>2</sub>)<sub>m1</sub>COOH][(CH<sub>2</sub>)<sub>n1</sub>COOH] with m<sub>1</sub> = 0 to 5 and n<sub>1</sub> = 0 to 5
- phosphono [(C<sub>1-5</sub>)alkyl]
- dihydroxyphosphonyloxy[(C<sub>1-5</sub>)alkyl]
- dimethoxyphosphonyl
- phosphono
- hydroxysulfonyl
- hydroxysulfonyl [(C<sub>1-5</sub>)alkyl] and
- hydroxysulfonyloxy [(C<sub>1-5</sub>)alkyl]

in neutral or charged form provided that at least one of the substituents X and Y is other than hydrogen and A and B are individually selected from the group consisting of oxygen, sulfur and -NH-.

**Claim 35** (previously presented) A compound of Claim 34 wherein at least one of X and Y is other than hydrogen in salt form with a non-toxic, pharmaceutically acceptable base.

**Claim 36** (currently amended) A compound of Claim 34 having the formula



(I')

wherein R<sub>1</sub> and R<sub>2</sub> are individually an acyl moiety derived from a saturated or unsaturated ~~carboxylic~~ carboxylic acid of 2 to 24 carbon atoms, unsubstituted or substituted with at least one member selected from the group consisting of hydroxyl, alkyl and alkoxy of 1 to 24 carbon atoms, amino, acyloxy of an organic carboxylic acid of 2 to 24 carbon atoms and acylamino and acylthio of an organic carboxylic acid of 2 to 24 carbon atoms and alkylthio of 1 to 24 carbon atoms, m, p and q are individually integers from 1 to 10, n is an integer from 0 to 10 and X and Y are individually hydrogen or phosphono.

**Claim 37** (previously presented) A compound of formula I of Claim 34 containing elements having (R) or (S) configuration, or racemates thereof.

**Claim 38** (previously presented) A compound of Claim 34 selected from the group consisting of 3-(3-dodecanoyloxytetradecanoylamino) 9-(3-hydroxytetradecanoylamino)-4-oxo-5-azadecan-1,10-diol, the 1-dihydrogenphosphate thereof and the 10-dihydrogenphosphate thereof, as well as the addition salts with an organic or a mineral base.

**Claim 39** (previously presented) A compound of Claim 34 selected from the group consisting of 3-(3-dodecanoyloxytetradecanoylamino) 9-(3-hydroxytetradecanoylamino)-4-oxo-5-azadecan-1,10-diol, 1, 10-bis-(dihydrogenphosphate) and its addition salts with an organic or a mineral base.

**Claim 40** (previously presented) A compound of Claim 34 selected from the group consisting of 3-(3-hydroxytetradecanoylamino)-9 -(3-dodecanoyloxytetradecanoylamino)-4-oxo-5-azadecan-1,10-diol, 1,10-bis-(dihydrogenphosphate) and its addition salts with an organic or a mineral base.


**Claim 41** (previously presented) A compound of Claim 34 selected from the group consisting of 3-(3-dodecanoyloxytetradecanoylamino) 9 -(3-hydroxytetradecanoylamino)-4-oxo-5-azadecan-1,10-diol, mono 1-dihydrogenphosphate and its addition salts with an organic or mineral base.

**Claim 42** (previously presented) A compound of Claim 34 selected from the group consisting of 3-(3-hydroxytetradecanoylamino)-9-(3-dodecanoyloxytetradecanoylamino)-4-

oxo-5-azadecan-1,10-diol, mono 1-dihydrogenphosphate and its addition salts with an organic or a mineral base.

**Claims 43 to 48** (cancelled).

**Claim 49** (currently amended)      A pharmaceutical composition containing as an active ingredient at least one compound of the formula I in accordance with Claim 34:



(I)

wherein R<sub>1</sub> and R<sub>2</sub> are each an acyl moiety of a saturated or unsaturated carboxylic acid of 2 to 24 carbon atoms, unsubstituted or substituted with at least one member selected from the group consisting of hydroxyl, alkyl and alkoxy of 1 to 24 carbon atoms, acyloxy of an organic carboxylic acid of 1 to 24 carbon atoms, acylamino and acylthio of a carboxylic acid of 1 to 24 carbon atoms and alkylthio wherein the alkyl group has from 1 to 24 carbon atoms,

m, p and q are integers from 1 to 10,

n is an integer from 0 to 10,

X and Y each are hydrogen or an acid group as defined in claim 34 either in neutral or charged form,

A and B are individually oxygen, sulfur or -NH-,

together or in admixture with a non-toxic, pharmaceutically acceptable, inert carrier.

**Claim 50** (previously presented)      The pharmaceutical composition in accordance with Claim 49, wherein the compound of formula I is a compound of the type where X and/or Y are phosphono and further A and B are an oxygen atom.

**Claim 51** (previously presented)      The pharmaceutical composition in accordance with Claim 49, wherein the active ingredient is in salt form with an organic or mineral base intended for therapeutic use.

**Claim 52** (previously presented)      The pharmaceutical composition in accordance with Claim 49, wherein the active ingredient is in the form of a pure enantiomer or in the form of a mixture of stereoisomers.

**Claim 53** (previously presented)      The method of inducing immuno-modulation in warm-blooded animals in need thereof comprising administering to said warm-blooded animals an immuno-modulating effective amount of a compound of Claim 34.

Cancel **Claims 54 to 56.**